Compare ESTA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTA | MIST |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | Costa Rica | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 176.3M |
| IPO Year | 2018 | N/A |
| Metric | ESTA | MIST |
|---|---|---|
| Price | $69.38 | $2.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $78.86 | $8.50 |
| AVG Volume (30 Days) | 454.4K | ★ 9.9M |
| Earning Date | 02-25-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,973,000.00 | N/A |
| Revenue This Year | $29.18 | N/A |
| Revenue Next Year | $24.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.76 | N/A |
| 52 Week Low | $26.56 | $0.63 |
| 52 Week High | $78.24 | $3.06 |
| Indicator | ESTA | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 43.69 |
| Support Level | $63.77 | $1.98 |
| Resistance Level | $75.00 | $2.10 |
| Average True Range (ATR) | 3.85 | 0.15 |
| MACD | -1.26 | -0.02 |
| Stochastic Oscillator | 39.12 | 22.89 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).